Genta's stock is depressed
Genta closed Thursday at $12.34 per share. The stock has lost 33% since hitting its 52-week high of $18.49 on March 22, despite news on Monday that it inked a Genasense
There are 250 Duchenne patients starting the process to receive reimbursement and treatment with Exondys 51, Sarepta says.
The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.
Vertex Pharmaceuticals is often mentioned as a takeover target, but the company is evaluating potential acquisitions and partnerships of its own to diversify beyond cystic fibrosis.
Results from two studies of next-generation "correctors" for cystic fibrosis, expected in the second half of 2017, will be stock-moving events.